In patients with new-onset IBD and PsA under treatment, the therapeutic choice will be conditioned by the PsA ongoing therapy. In case of treatment with MTX monotherapy, etanercept or anti IL-17, the therapy will need to be changed. The gene discussed is IL17A; the disease is inflammatory bowel disease.